Stocks · News reference

Lucid Diagnostics Announces Concert Issues Positive Coverage Policy Effective July 2026 For EsoGuard Esophageal DNA Test Across Its Client Health Plans

Aug 5, 2026, 12:48 PMBenzinga Newsdesk

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

SEC EDGAROct 16, 2026, 8:30 PMSEC EDGAR
8-K filing — Lucid Diagnostics Inc. (LUCD)
Filed: 2026-10-16 AccNo: 0001493152-26-047404 Size: 208 KB Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Item 9.01: Financial Statements and Exhibits
LUCD
BenzingaAug 27, 2026, 11:42 AMBenzinga Newsdesk
Ascendiant Capital Maintains Buy on Lucid Diagnostics, Raises Price Target to $9.5
Ascendiant Capital analyst Edward Woo maintains Lucid Diagnostics (NASDAQ:LUCD) with a Buy and raises the price target from $9.25 to $9.5.
LUCD
BenzingaAug 18, 2026, 12:13 PMPriya Nigam
Lucid Diagnostics Could Be 'High In The Queue' For Medicare Coverage Decision, Analyst Says
Lucid Diagnostics confirmed its first LBM win with Concert, opens up 10M covered lives. Analyst maintains Buy rating and $2.50 PT.
LUCD
BenzingaAug 17, 2026, 9:59 AMBenzinga Newsdesk
BTIG Reiterates Buy on Lucid Diagnostics, Maintains $2.5 Price Target
BTIG analyst Mark Massaro reiterates Lucid Diagnostics (NASDAQ:LUCD) with a Buy and maintains $2.5 price target.
LUCD